---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-003076"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:45:12.046556+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma receives FDA EOP2 support for AP-SA02 Phase 3 in S. aureus bacteremia

## Summary
- FDA confirmed Phase 2a diSArm data support advancement of AP-SA02 to a Phase 3 superiority study.
- Phase 3 study anticipated to initiate in the second half of 2026 in complicated S. aureus bacteremia.
- First bacteriophage company to advance a clinical candidate to Phase 3 for this indication.
- FDA is amenable to a request for Qualified Infectious Disease Product (QIDP) designation; Armata has submitted the request.
- Partnership with U.S. Department of Defense and significant shareholder Innoviva continues.

## SEC filing metadata
- accession: 0001104659-26-003076
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926003076/0001104659-26-003076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926003076/tm262898d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-003076
- JSON: https://secwatch.observer/filing/0001104659-26-003076.json
- Plain text: https://secwatch.observer/filing/0001104659-26-003076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.